Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AWK$142.08-0.67(-0.47%)American Water Contributes Expertise at California Water Association 2026 Summit American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., will join important conversations and contribute...[9:03:00 AM ET]TFC$48.91+0.47(+0.97%)Truist names Alex Bartlett regional president for Greater Washington and Maryland Truist Financial Corporation (NYSE: TFC) today announced Alex Bartlett has been named regional president for Greater Washington and Maryland. A...[9:03:00 AM ET]MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.03(-21.71%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]

HELP · NASDAQ

Cybin Inc.

$10.55 +0.23 (+2.23%)

Company overview

Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT for generalized anxiety disorder.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$654M
Employees
50
Headquarters
Toronto, ON
Website
cybin.com
CEO
Michael F. Cola
Listed
September 13, 2019
P/E
-1.69
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$139M
EBITDA
-$139M
Net income
-$145M
EPS
-$6.26
Total assets
$290M
Total debt
$0.00
Earnings yield
-59.34%

Price chart

3.306.389.4612.5315.61
HELP 1D NASDAQ O10.26H10.89L10.20C10.32+0.13 (+1.28%)Vol261.00K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
HELPCybin Inc. Press release Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development GlobeNewswire
HELPCybin Inc. Press release Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 GlobeNewswire
HELPCybin Inc. Press release Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors GlobeNewswire
HELPCybin Inc. Press release Helus Pharma to Host Investor Presentation on October 21, 2026 GlobeNewsWire
HELPCybin Inc. Press release Helus Pharma Announces Completion of Legal Name Change GlobeNewswire
HELPCybin Inc. Stock news Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression MarketBeat
HELPCybin Inc. Press release Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change GlobeNewsWire
HELPCybin Inc. Stock news Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board MarketBeat
HELPCybin Inc. Press release Helus Pharma to Participate at the TD Cowen 6th Annual GlobeNewswire
HELPCybin Inc. Press release Helus Pharma Presents New Analyses on HLP003 in Major GlobeNewswire
HELPCybin Inc. Stock news Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 MarketBeat
TCRT Stock news Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Benzinga
HELPCybin Inc. Press release Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York GlobeNewswire
HELPCybin Inc. Press release Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York GlobeNewswire
HELPCybin Inc. Press release Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York GlobeNewswire
HELPCybin Inc. Press release Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board GlobeNewsWire
HELPCybin Inc. Press release Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights GlobeNewsWire
HELPCybin Inc. Press release Helus Pharma Appoints Michael Halstead as Chief Executive Officer GlobeNewsWire
HELPCybin Inc. Press release CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health GlobeNewsWire
HELPCybin Inc. Press release Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference GlobeNewsWire
See more
FAQ

Questions about Cybin Inc.

What does Cybin Inc. do?
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT for generalized anxiety disorder.
What is HELP's market cap?
Cybin Inc. (HELP) is a listed stock with a live quote. The latest market cap on this page is $654M.
Where is Cybin Inc. headquartered?
Cybin Inc. is headquartered in Toronto, ON.
How do I get HELP news from the API?
Call GET /v1/news?tickers=HELP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does HELP news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for HELP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the HELP price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs